The HER-2/neu proto-oncogene is overexpressed in 20-30% of human breast cancers and is associated with high recurrence risk. The oncogenic potential of HER-2/neu, together with its elevated expression in tumors, cell surface localization, and immunogenicity in some patients, make this oncoprotein an ideal target for immunotherapeutic approaches. To test the efficacy of immune-based strategies in eliciting an antitumor response, we used the N#202 transgenic mouse model engineered to overexpress the rat neu proto-oncogene under the control of the mouse mammary tumor virus promoter; females of this line develop spontaneous focal mammary tumors by 6 months of age. Transgenic mice immunized intramuscularly with a HER-2 cDNA ligated into the VR1012 (VICAL) expression vector under the control of the cytomegalovirus promoter developed signifiKeywords: DNA vaccination; proto-neu-transgenic mice; breast cancer Genetic alterations of human HER-2/neu proto-oncogene occur in 20-30% of breast cancers, and overexpression of the oncoprotein induces cell transformation and correlates with poor clinical outcome.
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use of rat neu as immunogen and FVB mice transgenically expressing proto-neu 8, 9 or mutated neu 10 as host. Different plasmid DNA constructs encoding mutated or wild-type human and rat HER-2/neu full-length or deleted genes in Balb/c and FVB mice transgenic for the mutated neu gene 11 have also been used. 12, 13 Because parental FVB or Balb/c mice are not tolerant to rat neu or because of the possible immunogenicity of the mutated neu gene, these models might not be representative of the human scenario. However, the questions of whether vaccine- and we therefore turned to a different form of in vivo neu-mimicking immunogen based on the discovery that inoculation of plasmid DNA can induce specific and long-lasting immunity in vivo in a variety of ag. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] To break immune tolerance against rat neu in N#202 mice and to address the issue of host tolerance to naturally expressed tumor ag, we constructed a plasmid DNA vector encoding the full-length cDNA for the human HER-2/neu proto-oncogene (VR1012/HER-2) driven by the cytomegalovirus (CMV) early promoter/ enhancer and used it as immunogen since immunization against heterologous proteins can induce immune reactions against the corresponding 'self' antigen, through shared epitopes. For example, DNA vaccination against human melanoma antigen GP100 has been shown to induce cross-reactive CTL responses against the murine homologue of GP100. 27 The VR1012/HER-2 plasmid vector was derived by cloning a 4100-bp XhoI fragment containing the entire human HER-2 ORF into SalI sites of plasmid VR1012 (VICAL, San Diego, CA, USA); insert orientation was checked by restriction enzyme digestion. The ability of VR1012/HER-2 to induce HER-2 expression was confirmed by Western blot analysis of lysates from COS-7 Chinese hamster ovary cells transiently transfected by the lipofectin method (data not shown).
A preliminary observation suggested that only when immunizations were started early tumor protection could be achieved. These experiments were repeated with appropriate controls. As shown in Figure 1a , a significant preventive effect was clearly seen in mice immunized with VR1012/HER-2 vaccine starting at 12 weeks of age as compared with mice injected with empty vector (P Ͻ 0.0001) or mice left untreated (P = 0.0006). By contrast, no differences between VR1012/HER-2 vaccinated and control mice in tumor incidence were observed when immunizations were started in 24-week-old mice (Figure 1b) . The negligible efficacy of the late treatment was further confirmed in another experiment.
Presumably, the delayed onset and significant decrease in tumor incidence in the early-immunized N#202 mice as compared with mice immunized beginning at 24 weeks, reflects the histopathologic status of the mammary glands at the time of the beginning of vaccination, 8, 28, 29 ie normal tissue without hyperplasia at 12 weeks versus unpalpable sporadic malignant foci at 24 weeks (Figure 2) . Thus, effective vaccination of N#202 mice appears to depend on the early timing of immunization, before the onset of tumorigenesis. Consistent with previous studies, 9 the tumors that did develop in the vaccinated mice grew with the same kinetics as tumors in the control groups (data not shown). FACS analysis of these tumors revealed overexpression of the rat HER2/neu oncoprotein (Figure 3 ), indicating that no selection for HER2/neu-negative cells had occurred.
From a practical standpoint, DNA immunization relies on in vivo transfection, production and possibly secretion of the transgene product, and ag presentation by specialized cells. However, in most studies, transduced cells in vivo have not been identified. Although it remains unclear whether the non-responder vaccinated mice in our study succeeded in taking up, expressing and processing VR1012/HER-2 DNA, immunohistochemical analysis did reveal evidence of human HER-2/neu gene product expression at the site of DNA injection between 48 and 72 h after plasmid inoculation (data not shown).
A specific anti-human HER-2/neu humoral response was detected in the early-immunized N#202 mice ( Figure 4) ; however no difference in the antibody profile was found between mice that developed tumors and those that did not. Thus, B cell immunity does not appear to play a major role in the inhibition of tumor development. To evaluate the cellular immune response against human HER2/neu, the murine neu-nonexpressing tumor cell line N202.1E was transfected with the human a b HER2/neu gene. Figure 5 shows the expression of human HER-2 oncoprotein in these transfected cl#5G5 cells, derived from N202.1E murine syngeneic mammary tumor cells. cl#5G5 cells were maintained in G418 (0.5 mg/ml) selection medium and used as target in a standard 51 Cr-release assay. CTL responses ( Figure 6 ) were evaluated after restimulation of splenocytes in mixed lymphocyte-tumor cell culture (MLTC) with irradiated syngeneic cells expressing either rat neu (N202.1A) or human HER-2/neu (cl#5G5). CTL activity against cl#5G5 was observed only in cultures with cl#5G5 and splenocytes from 4 different VR1012/HER-2-immunized tumor-free mice. However, these CTLs failed to lyse syngeneic cells expressing only the rat neu (Figure 6a -c shows representative data from two VR1012/HER-2-vaccinated mice and from a control mouse of one experiment of two performed). The cyto- 33 lytic activity against cl#5G5 cells appeared to be CD3/T cell receptor-dependent, as indicated by dose-dependent inhibition by anti-CD3 antibodies (Figure 6d and e) . The present study demonstrates that an active immunotherapeutic manipulation of an oncogene product, exploiting a plasmid DNA vaccine, can significantly protect against spontaneous tumor development in N#202 mice on the basis of the timing of neu-specific vaccination. The lack of a detectable immune response cross-reactive with rat neu in our study, at present prevents conclusions about the mechanism by which specific anti-HER2/neu immune responses inhibit tumor development in the gene-vaccinated mice. Even if no antigen-specific response was demonstrated, it is possible that the activation of cell-mediated immunity (as demonstrated by the anti-HER-2 CTL response) leads to the release of cytokines that induce other downstream factors, such as NK cell activation. Indeed, our preliminary data indicate that splenocytes from VR1012/HER-2-vaccinated mice secrete interferon-(IFN)-␥ in response to both human and rat neu-expressing cells. Increased levels of IFN-␥ can directly inhibit tumor cell proliferation, or can stimulate the release of anti-angiogenic cytokines such as monokine induced by IFN-␥ (MIG) and IFN-inducible protein 10 (IP-10) which prevent the angiogenesis needed for tumor development. 28 Alternatively, CpG motifs present in the Vical vector backbone might enhance the response to the HER-2 ag. 30 The histopathology and morphology of mammary tissues and tumors, the specific antibody and cellular antitumor immune responses, combined with inflammatory response and cytokine release by immunocompetent cells, are all under investigation in gene-vaccinated and control mice to elucidate fully the mechanism(s) underlying the efficacy of our vaccination protocol.
Vaccines designed to generate an immune response against a self-protein raise safety concerns. We detected no autoimmune toxicity in our in vivo experiments as expected since no cross-reactive response to mouse neu was observed. In any case, the overexpression of HER-2/neu in tumors is expected to confer some selectivity of the immune response without autoimmune toxicity in tissues expressing basal levels of HER-2/neu, as supported by data obtained in patients bearing HER-2/neupositive metastatic breast and ovarian cancers and vaccinated with oncoprotein-derived peptides. 31 While HER-2/neu gene vaccination might not be effective in all patients, it holds promise as a beneficial adjunct to current standard cancer therapy approaches.
